Switch theme
Sign up to access all valuation multiples
Hualan Biological Vaccine Inc is engaged in Research, development, production and sales of human vaccines.
2005
n/a
LTM Revenue $157M
LTM EBITDA $143M
$1.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hualan Biological Vaccine has a last 12-month revenue (LTM) of $157M and a last 12-month EBITDA of $143M.
In the most recent fiscal year, Hualan Biological Vaccine achieved revenue of $157M and an EBITDA of $50.4M.
Hualan Biological Vaccine expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hualan Biological Vaccine valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $157M | XXX | $157M | XXX | XXX | XXX |
| Gross Profit | $128M | XXX | $128M | XXX | XXX | XXX |
| Gross Margin | 81% | XXX | 81% | XXX | XXX | XXX |
| EBITDA | $143M | XXX | $50.4M | XXX | XXX | XXX |
| EBITDA Margin | 91% | XXX | 32% | XXX | XXX | XXX |
| EBIT | $30.0M | XXX | $24.1M | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $28.7M | XXX | $28.7M | XXX | XXX | XXX |
| Net Margin | 18% | XXX | 18% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 17, 2025, Hualan Biological Vaccine's stock price is CNY 17 (or $2).
Hualan Biological Vaccine has current market cap of CNY 10.3B (or $1.4B), and EV of CNY 8.4B (or $1.2B).
See Hualan Biological Vaccine trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.2B | $1.4B | XXX | XXX | XXX | XXX | $0.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 17, 2025, Hualan Biological Vaccine has market cap of $1.4B and EV of $1.2B.
Hualan Biological Vaccine's trades at 7.5x EV/Revenue multiple, and 23.3x EV/EBITDA.
Equity research analysts estimate Hualan Biological Vaccine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hualan Biological Vaccine has a P/E ratio of 50.2x.
See valuation multiples for Hualan Biological Vaccine and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV/Revenue | 7.5x | XXX | 7.5x | XXX | XXX | XXX |
| EV/EBITDA | 8.2x | XXX | 23.3x | XXX | XXX | XXX |
| EV/EBIT | 39.2x | XXX | 48.9x | XXX | XXX | XXX |
| EV/Gross Profit | 9.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 50.2x | XXX | 50.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 20.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHualan Biological Vaccine's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Hualan Biological Vaccine's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hualan Biological Vaccine's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Hualan Biological Vaccine and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | 91% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 44% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 66% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hualan Biological Vaccine acquired XXX companies to date.
Last acquisition by Hualan Biological Vaccine was XXXXXXXX, XXXXX XXXXX XXXXXX . Hualan Biological Vaccine acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Hualan Biological Vaccine founded? | Hualan Biological Vaccine was founded in 2005. |
| Where is Hualan Biological Vaccine headquartered? | Hualan Biological Vaccine is headquartered in China. |
| Is Hualan Biological Vaccine publicy listed? | Yes, Hualan Biological Vaccine is a public company listed on SHE. |
| What is the stock symbol of Hualan Biological Vaccine? | Hualan Biological Vaccine trades under 301207 ticker. |
| When did Hualan Biological Vaccine go public? | Hualan Biological Vaccine went public in 2022. |
| Who are competitors of Hualan Biological Vaccine? | Similar companies to Hualan Biological Vaccine include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Hualan Biological Vaccine? | Hualan Biological Vaccine's current market cap is $1.4B |
| What is the current revenue of Hualan Biological Vaccine? | Hualan Biological Vaccine's last 12 months revenue is $157M. |
| What is the current EV/Revenue multiple of Hualan Biological Vaccine? | Current revenue multiple of Hualan Biological Vaccine is 7.5x. |
| Is Hualan Biological Vaccine profitable? | Yes, Hualan Biological Vaccine is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Hualan Biological Vaccine? | Hualan Biological Vaccine's last 12 months EBITDA is $143M. |
| What is Hualan Biological Vaccine's EBITDA margin? | Hualan Biological Vaccine's last 12 months EBITDA margin is 91%. |
| What is the current EV/EBITDA multiple of Hualan Biological Vaccine? | Current EBITDA multiple of Hualan Biological Vaccine is 8.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
